Tutte le immagini(1)

Documenti

CdO/CdA

1344702

USP

Iopamidol

Name: Iopamidol
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

(S)-N,N′-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):

C₁₇H₂₂I₃N₃O₈

Numero CAS:

60166-93-0

Peso molecolare:

777.09

Codice UNSPSC:

41116107

NACRES:

NA.24

Grado

pharmaceutical primary standard

Famiglia di API

iopamidol

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

InChI

1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
XQZXYNRDCRIARQ-LURJTMIESA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Iopamidol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Iopamidol Injection

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo

Descrizione

Determinazione del prezzo

1344746

1344724

1344735

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 1

1 of 1

Supelco

PHR1931

Iohexol

In vivo evaluation of fibrous cap thickness by optical coherence tomography for positive remodeling and low-attenuation plaques assessed by computed tomography angiography.

Akira Sato et al.

International journal of cardiology, 182, 419-425 (2015-01-18)

Coronary plaques with positive remodeling (PR) and low-attenuation plaques (LAP) by computed tomography angiography (CTA) might be associated with plaque vulnerability. The purpose of this study was to assess the relation between coronary plaques with PR and LAP by CTA

Improving the diagnostic performance of the real world coronary computed tomography angiography including uninterpretable segments.

Nobuo Tomizawa et al.

International journal of cardiology, 176(3), 975-979 (2014-09-07)

The purpose was to investigate the diagnostic performance of coronary computed tomography angiography (CTA) when non-calcified uninterpretable segments were determined as either obstructive or patent. We also investigated the factors that could improve the diagnosis of CTA. A total of

Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.

Joseph B Muhlestein et al.

JAMA, 312(21), 2234-2243 (2014-11-18)

Coronary artery disease (CAD) is a major cause of cardiovascular morbidity and mortality in patients with diabetes mellitus, yet CAD often is asymptomatic prior to myocardial infarction (MI) and coronary death. To assess whether routine screening for CAD by coronary

Association of nonculprit plaque characteristics with transient slow flow phenomenon during percutaneous coronary intervention.

Katsuya Miura et al.

International journal of cardiology, 181, 108-113 (2014-12-17)

The slow flow (SF) phenomenon is more prevalent in patients with acute coronary syndrome (ACS), who frequently exhibit vulnerable plaques in remote coronary arteries. We aimed to clarify the impact of nonculprit plaque characteristics on the occurrence of SF using

Quantitative assessment of right ventricular function and pulmonary regurgitation in surgically repaired tetralogy of Fallot using 256-slice CT: comparison with 3-Tesla MRI.

Yuzo Yamasaki et al.

European radiology, 24(12), 3289-3299 (2014-08-13)

To compare 256-slice cardiac computed tomography (CCT) with cardiac magnetic resonance (CMR) imaging to assess right ventricular (RV) function and pulmonary regurgitant fraction (PRF) in patients with repaired tetralogy of Fallot (TOF). Thirty-three consecutive patients with repaired TOF underwent retrospective

Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.